Recurrent Melanoma Recruiting Phase 2 Trials for DB09035 (Nivolumab)

IndicationStatusPhase
DBCOND0028662 (Recurrent Melanoma)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02465060NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple MyelomaTreatment
NCT03050060Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney CancerTreatment